Drug's 'double hit' overcomes leukaemia resistance
A drug that uses a unique double hit to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, majority funded by Cancer Research UK, is published this week in Leukaemia.
Around 30 per cent of patients with AML have faults in the FLT3 gene, which are linked to more aggressive leukaemias and poor survival. While drugs that target these faults are available, the disease eventually builds resistance, leaving treatments ineffective.
To combat this, researchers at The Institute of Cancer Research (ICR) in London, funded by Cancer Research UK and Breakthrough Breast Cancer, developed a unique drug that targets AML cells in a double hit. The drug blocks the protein made by the faulty FLT3 gene along with another key protein called Aurora kinase which are both involved in driving cancer growth.
In healthy blood cells, FLT3 sends a signal to the cells telling them when to proliferate, while Aurora kinase plays a role in cell division. Leukaemia cells with faulty FLT3 can proliferate out of control, while many cancer cells have higher levels of Aurora kinase, causing errors during cell division. This double hit drug blocks both mechanisms that otherwise promote leukaemia growth.
The drug is also unique because it can destroy cells even if they develop new faults in the FLT3 genes that would make them resistant to other inhibitors.
The combination led to complete remission in half of the mice treated with this drug, compared with only 25 per cent with an existing drug that only blocks FLT3.
Lead author Dr. Spiros Linardopoulos, leader of the Cancer Drug Target Discovery Team at The Institute of Cancer Research said: There has been great interest in using FLT3 drugs to treat AML, but their effectiveness has been limited because leukaemia cells gain new mistakes in the FLT3 gene, causing resistance.
Our new drug has the potential to overcome this and has a range of possible uses in AML as a first line of attack for patients with faulty FLT3, in particular in those over 60 who dont tolerate chemotherapy well, and also to treat leukaemia patients who have relapsed.
Professor Paul Workman, director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: Were excited about the potential of our new double hit drug and are now planning to take it into clinical trials to see if it is effective in patients.
The faults that occur in the FLT3 gene cause rapid cell division, and one particular mistake is linked to a very poor outcome in both adults and children with AML. Each year around 2,380 people are diagnosed with AML in the UK.
Dr. Julie Sharp, senior science information manager at Cancer Research UK, said: Cancer Research UK has a long history of developing drugs to treat leukaemia more effectively. But designing treatments that overcome resistance is a major challenge for researchers.
By creating cells in the lab that mimic how drug resistance develops in AML the researchers were able to show that their new drug delivers a double hit to halt cancer cells in their tracks. Next they will test the new drug in patients to see if it has the potential to treat people with aggressive AML.
More information: Moore AS (2012). Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia , 26 (7) PMID: 22354205
Provided by Cancer Research UK
- Scientists find new drug target for hard-to-treat leukaemia Mar 30, 2012 | not rated yet | 0
- Scientists discover how to beat resistance to standard leukaemia drug Dec 09, 2011 | not rated yet | 0
- Cancer Research UK launches trial of new drug to treat acute childhood leukaemia Jan 27, 2012 | not rated yet | 0
- Combination therapy with midostaurin improves survival of AML patients with FLT3 mutations, phase 1 Dec 08, 2009 | not rated yet | 0
- Cell death researchers identify new Achilles heel in acute myeloid leukemia Jan 17, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
22 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer 10 hours ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer 11 hours ago | not rated yet | 0
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer 12 hours ago | not rated yet | 0
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 13 hours ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 15 hours ago | not rated yet | 0
Is it permissible to harm one to save many? Those who tend to say "yes" when faced with this classic dilemma are likely to be deficient in a specific kind of empathy, according to a report published in the scientific journal ...
10 minutes ago | not rated yet | 0 |
Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens
Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...
1 hour ago | not rated yet | 0 |
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
17 hours ago | 4.2 / 5 (5) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
15 hours ago | 4.9 / 5 (13) | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
17 hours ago | 4.6 / 5 (7) | 0 |